Search clinical trials for: Racemic formoterol

Total 590 results

Tanta University

Completed

Three Treatment of Chronic Obstructive Pulmonary Disease Patients

COPD
Boehringer Ingelheim

Completed

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Asthma

United States
AstraZeneca

Completed

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma (Spacer)

Asthma

Russian Federation, Hungary, Poland
Sunovion

Completed

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Chronic Obstructive Pulmonary Disease

United States
Novartis
Schering-Plough

Completed

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

France, Germany, Belgium, Italy, Turkey, Hungary, Argentina, Peru, United Kingdom, South Africa, Latvia, Lithuania, Romania, Chile, Ireland, Norway, Poland
Novartis
Schering-Plough

Completed

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

Asthma

United States, Colombia, Peru
Treague Ltd
Medicines for Malaria Venture

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine

Healthy Subjects

United Kingdom
Brian J Lipworth

Completed

Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD) (FARD12)

COPD

United Kingdom
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
Dartmouth-Hitchcock Medical Center
Sunovion

Completed

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma

Asthma

Sweden
Federal University of São Paulo

Completed

Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema | Chronic Bronchitis

Brazil
Università degli Studi di Ferrara

Completed

Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma

Asthma

Italy
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte (ADECO)

Asthma

Germany
Dey

Completed

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca

Completed

Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD (CODEX)

Chronic Obstructive Pulmonary Disease

Germany, Switzerland
AstraZeneca

Completed

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia (SMARTASIA)

Asthma

China, Taiwan, Thailand, India, Indonesia
AstraZeneca

Completed

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

Asthma
AstraZeneca

Completed

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Asthma
AstraZeneca

Completed

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler

Stable Asthma
AO GENERIUM

Completed

An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma (NAP)

Bronchial Asthma

Russian Federation
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Consorzio Futuro in Ricerca

Completed

Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (PMC-101-APT)

Asthma | COPD

Italy
University of California, Los Angeles
Sunovion

Unknown

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography

Chronic Obstructive Pulmonary Disease | Emphysema | COPD | Chronic Bronchitis

United States
Rajavithi Hospital

Withdrawn

Efficacy of Topical 95% TCA in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test

CIN1 | Trichloroacetic Acid

Thailand
AstraZeneca

Completed

Symbicort in Asthmatic Children - SEEDLING

Asthma
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

Chronic Obstructive Pulmonary Disease

United States, Bulgaria, Germany, Hungary, Romania, Denmark, Greece, Mexico, Iceland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (ELIOT)

Asthma

United Kingdom
Sunovion

Completed

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

Asthma

United States
Maastricht University Medical Center

Completed

Vinegar Co-ingestion in Type 2 Diabetes

Type 2 Diabetes Mellitus

Netherlands
AstraZeneca

Completed

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

COPD Method Evaluation | Chronic Obstructive Pulmonary Disease Method Evaluation

United Kingdom, Sweden
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Institut... and other collaborators

Completed

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis (CANHPARI)

Neutropenia | Hematopoietic Stem Cell Transplantation | Hematological Malignancies | Invasive Fungal Disease | Chronic Disseminated Candidiasis

France
Brigham and Women's Hospital

Completed

Replication of the P04334 Asthma Trial in Healthcare Claims Data

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
AstraZeneca

Completed

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Asthma

United States, Puerto Rico
Meir Medical Center

Unknown

Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic

Asthma Exacerbation

Israel
Novartis

Completed

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lung Diseases, Obstructive | Pulmonary Disease, Chronic Obstructive | COPD

United States, Germany, Spain, Argentina, Italy, Turkey, Canada, India, Sweden, Korea, Republic of, Taiwan, Puerto Rico
AstraZeneca

Completed

Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT

Asthma
AstraZeneca

Terminated

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

Asthma, Bronchial

Spain
AstraZeneca

Completed

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

Asthma
Orion Corporation, Orion Pharma

Completed

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product (BUFODIL)

Asthma

Bulgaria
Andrew Chung
More Foundation; Banner Health

Unknown

Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion

Postoperative Pain | Dysphagia | Dysphonia

United States
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers (TRIPLE 1)

COPD

Belgium
Catholic University, Italy

Completed

Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

Asthma

Italy
Mizkan Holdings Co., Ltd.
ObvioHealth; Endothelix

Unknown

Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10% (Rice-vinegar)

Prehypertension

United States
Cipla Ltd.

Completed

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

Asthma

United States
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)

Asthma
Orion Corporation, Orion Pharma

Completed

Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland

3

Subscribe